Related Experiment Video
Updated: Oct 20, 2025
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1
Guadalupe Oñate1, Alex Bataller2, Ana Garrido1
1Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain.
Abstract:
The negative prognostic impact of internal tandem duplication of FLT3 (FLT3-ITD) in patients with acute myeloid leukemia with mutated NPM1 (AML-NPM1) is restricted to those with a higher FLT3-ITD allelic ratio (FLT3high; ≥0.5) and considered negligible in those with a wild-type (FLT3WT)/low ITD ratio (FLT3low). Because the comutation of DNMT3A (DNMT3Amut) has been suggested to negatively influence prognosis in AML-NPM1, we analyzed the impact of DNMT3Amut in FLT3-ITD subsets (absent, low, and high ratios). A total of 164 patients diagnosed with AML-NPM1 included in 2 consecutive CETLAM protocols and with DNMT3A and FLT3 status available were studied. Overall, DNMT3Amut status did not have a prognostic impact, with comparable overall survival (P = .2). Prognostic stratification established by FLT3-ITD (FLT3WT = FLT3low > FLT3high) was independent of DNMT3Amut status. Measurable residual disease (MRD) based on NPM1 quantitative polymerase chain reaction was available for 94 patients. DNMT3Amut was associated with a higher number of mutated NPM1 transcripts after induction (P = .012) and first consolidation (C1; P < .001). All DNMT3Amut patients were MRD+ after C1 (P < .001) and exhibited significant MRD persistence after C2 and C3 (MRD+ vs MRD-; P = .027 and P = .001, respectively). Finally, DNMT3Amut patients exhibited a trend toward greater risk of molecular relapse (P = .054). In conclusion, DNMT3Amut did not modify the overall prognosis exerted by FLT3-ITD in AML-NPM1 despite delayed MRD clearance, possibly because of MRD-driven preemptive intervention.
Insights
In acute myeloid leukemia with mutated NPM1, DNMT3A mutations do not alter overall survival but are linked to delayed measurable residual disease clearance. This suggests preemptive interventions may mitigate relapse risk.
Area of Science:
- Hematology
- Molecular Biology
- Oncology
Background:
- Internal tandem duplication of FLT3 (FLT3-ITD) negatively impacts prognosis in acute myeloid leukemia with mutated NPM1 (AML-NPM1), particularly at high allelic ratios.
- The comutation of DNMT3A (DNMT3Amut) has been hypothesized to worsen prognosis in AML-NPM1, but its specific impact across different FLT3-ITD statuses is unclear.
Purpose of the Study:
- To investigate the prognostic impact of DNMT3Amut in AML-NPM1 patients stratified by FLT3-ITD allelic ratios (absent, low, and high).
- To assess the association between DNMT3Amut and measurable residual disease (MRD) kinetics and molecular relapse risk.
Main Methods:
- Analysis of 164 AML-NPM1 patients from two CETLAM protocols with available DNMT3A and FLT3 mutation status.
- Stratification based on FLT3-ITD allelic ratio: FLT3WT/low and FLT3high.
- Quantification of NPM1 measurable residual disease (MRD) using quantitative polymerase chain reaction in a subset of 94 patients.
Main Results:
- DNMT3Amut status did not significantly affect overall survival, irrespective of FLT3-ITD status.
- DNMT3Amut was associated with higher NPM1 transcript levels post-induction and after first consolidation (C1).
- All DNMT3Amut patients were MRD-positive after C1, showing significant MRD persistence after C2 and C3, and a trend toward increased molecular relapse risk.
Conclusions:
- DNMT3Amut does not alter the overall prognostic impact of FLT3-ITD in AML-NPM1.
- Despite delayed MRD clearance in DNMT3Amut patients, preemptive MRD-driven interventions may prevent adverse outcomes.
- Further research into MRD-guided therapy is warranted for this patient subgroup.
